Update on immunotherapy in melanoma

Surgical Oncology Clinics of North America

Volumn 24, Issue 2, 2015, Pages 337-346

  Green, Jamie ^a   Ariyan, Charlotte ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adaptive immunity; Antitumor immunity; Costimulatory blockade; Immunotherapy; Innate immunity; Metastatic melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; DACARBAZINE; IMIQUIMOD; INTERLEUKIN 2; IPILIMUMAB; MELANOCYTE PROTEIN PMEL 17; NIVOLUMAB; ONAMELATUCEL L; PLACEBO; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLITIS; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; ENDOCRINE DISEASE; FEVER; HEPATITIS; HUMAN; HYPOTENSION; INFECTION; LIMB SWELLING; LIVER TOXICITY; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; NAUSEA; NEURITIS; NONHUMAN; RASH; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VOMITING; IMMUNOLOGY; IMMUNOTHERAPY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS;

EID: 84926120027     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2014.12.010     Document Type: Review

References (34)

1. Cann S.A., van Netten J.P., van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postrgrad Med J 2003, 79:672-680.
2. Goldsby R.A., Kindt T.J., Osborne B.A. Immunology 2000, W.H. Freedman and Company, New York. 4th edition.
3. American Cancer Society. Melanoma skin cancer. Available at: Accessed August 7, 2014. http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-key-statistics.
4. Smyth M.J. Lloyd John Old 1933-2011. Nature Immunology 2012, 13:103.
5. Brandau S., Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007, 61:299-305.
6. Morton D.L., Eilber F.R., Holmes E.C., et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 1974, 180(4):635-643.
7. Morton D.L., Hsueh E.C., Essner R., et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002, 236(4):438-448. [discussion: 448-9].
8. Kidner T.B., Morton D.L., Lee D.J., et al. Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. JImmunother 2012, 35(9):716-720.
9. Amin A., White R.L. High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?. Oncology 2013, 27:680-691.
10. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1982 and 1993. JClin Oncol 1999, 17:2105-2116.
11. Batus M., Waheed S., Ruby C., et al. Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol 2013, 14:179-194.
12. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271(5256):1734-1736.
13. Peggs K.S., Quezada S.A., Chambers C.A., et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. JExp Med 2009, 206(8):1717-1725.
14. Simpson T.R., Li F., Montalvo-Ortiz W., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. JExp Med 2013, 210(9):1695-1710.
15. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363:711-723.
16. Schadendorf D, Hodi FS, Robert C, etal. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Presented at the 2013 European Cancer Congress. Amsterdam, September 27-October 1, 2013.
17. Prieto P.A., Yang J.C., Sherry R.M., et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012, 18(7):2039-2047.
18. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. NEngl J Med 2011, 364:2517-2526.
19. Wolchok J.D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15(23):7412-7420.
20. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. NEngl J Med 2012, 366(26):2443-2454.
21. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. NEngl J Med 2012, 366(26):2455-2465.
22. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. NEngl J Med 2013, 369(2):122-133.
23. Sznol M., Kluger H.M., Callahan M.K., et al. Survival, response duration, and activity by BRAF mutation status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma. JClin Oncol 2014, 32(5S Suppl). Abstract: LBA9003.
24. Phan G.Q., Rosenberg S.A. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 2013, 20(4):289-297.
25. Besser M.J., Shapira-Frommer R., Treves A.J., et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010, 16:2646-2655.
26. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281.
27. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med 2011, 365:725-733.
28. Johnson L.A., Morgan R.A., Dudley M.E., et al. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3):535-546.
29. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12(4):252-264.
30. Vinay D.S., Kwon B.S. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012, 11(5):1062-1070.
31. Hirschhorn-Cymerman D., Rizzuto G.A., Merghoub T., et al. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. JExp Med 2009, 206(5):1103-1116.
32. Cohen A.D., Schaer D.A., Liu C., et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010, 5(5):e10436.
33. Ascierto P.A., Simeone E., Sznol M., et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010, 37(5):508-516.
34. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. NEngl J Med 2006, 355(10):1018-1028.